Actavis Completes Purchase of Serbia’s Zdravlje for $9.2 Million

Actavis Inc., the world’s fourth biggest maker of generic drugs, bought the entire equity of Serbia’s FHI Zdravlje AD as small shareholders sold their stock.

Actavis started the buyout on Nov. 2 to acquire 26.7 percent of the company it didn’t own and completed it at the cost of more than 7 million euros ($9.2 million), the company said in an e-mailed statement today.

Leskovac, Serbia-based Zdravlje was bought in 2002 for 3.5 million euros. Actavis said it invested more than 50 million euros in the plant, including the buyout.

Before it's here, it's on the Bloomberg Terminal.